Clinical Trials Logo

H3 K27M Glioma clinical trials

View clinical trials related to H3 K27M Glioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02525692 Active, not recruiting - Glioblastoma Clinical Trials

Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma

Start date: January 2016
Phase: Phase 2
Study type: Interventional

ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation.